ライフサイエンスコーパス: valproic acid

1 nacetin, metribuzin, phenytoin, thiacloprid, valproic acid).

2 liperidone is similar to that of lithium and valproic acid.

3 when given patients with acute ingestions of valproic acid.

4 he so-called "mood stabilizers," lithium and valproic acid.

5 s of lamotrigine and phenobarbital caused by valproic acid.

6 , suppressed the transcriptional response to valproic acid.

7 well as Sp-mediated transcription induced by valproic acid.

8 monitored in all hepatitis C patients taking valproic acid.

9 me, accompanied by an increase in the use of valproic acid.

10 genic mechanisms of the teratogenic compound valproic acid.

11 ion options for carbamazepine, diazepam, and valproic acid.

12 pecially among those using carbamazepine and valproic acid.

13 iability: ethanol and the antiepileptic drug valproic acid.

14 y relevant AEDs ethosuximide, lacosamide, or valproic acid.

15 treatment while enhanced in the presence of valproic acid.

16 bined with the histone-deacetylase inhibitor valproic acid.

17 gent, 5-azacytidine, and the HDAC inhibitor, valproic acid.

18 levetiracetam, 1.40 (95% CI, 1.19-1.64) for valproic acid, 1.02 (95% CI, 0.71-1.47) for phenytoin, a

19 levetiracetam, 1.40 (95% CI, 1.23-1.59) for valproic acid, 1.16 (95% CI, 0.88-1.51) for phenytoin, a

20 vs 4047 hospitalizations [87.0%]; P < .001), valproic acid (109 hospitalizations [1.3%] vs 256 hospit

21 th ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar with respect to their d

22 Valproic acid (2 mmolkg for 15 days, twice a day) revert

23 repurposed drugs such as phenylbutyrate (2), valproic acid (3), riluzole (6), hydroxyurea (7), and al

24 bumin in the absence or presence of vehicle, valproic acid (300 mug/g body weight) or BAY11-7082 (400

25 to prevent the spread of HIV, we added oral valproic acid 500-750 mg twice daily to their treatment

26 ffects of polymyxin-B (a cytolytic peptide), valproic acid (a lipophilic drug), and amyloid-beta (a p

27 nd lenalidomide had synergistic effects with valproic acid [a histone deacetylase (HDAC) inhibitor] b

28 Both valproic acid, a class I HDAC inhibitor, and suberoylani

29 roduce infectious viruses in the presence of valproic acid, a histone deacetylase inhibitor and a nov

30 Moreover, valproic acid, a histone deacetylase inhibitor that we p

31 Combining P-cDR5 with valproic acid, a histone deacetylase inhibitor, resulted

32 Finally, embryos treated with valproic acid, a known teratogen which affects somite se

33 ns experimentally, we exposed rat embryos to valproic acid, a second teratogen newly linked to autism

34 , including the selective class I antagonist valproic acid, activate the same genes prematurely and a

35 We report that valproic acid activates Wntdependent gene expression, si

36 Here, we show that valproic acid addition to liquid cultures of human CD34+

37 r in rat brain also was reduced by long-term valproic acid administration.

38 DACi (apicidin, MS-275, sodium butyrate, and valproic acid) all inhibit by approximately 90% TF activ

39 The local diffusion constants for valproate/valproic acid along the bilayer normal are found to be a

40 Finally, valproic acid also attenuated METH-induced decrease H4K1

41 cetylase inhibitors trichostatin A (TSA) and valproic acid also induced expression of the endogenous

42 y ASD risk factors, including HDAC inhibitor valproic acid and a variety of endocrine factors, xenobi

43 Valproic acid and BAY11-7082 selectively diminished tumo

44 Both valproic acid and BAY11-7082 significantly attenuated th

45 We show that histone deacetylase inhibitors valproic acid and butyrate dampened AICDA/Aicda (AID) an

46 Anticonvulsant mood stabilizers, e.g., valproic acid and carbamazepine, and atypical antipsycho

47 As with valproic acid and carbamazepine, zonisamide (12.5 and 25

48 review the pathophysiology and toxicology of valproic acid and determine whether the literature suppo

49 , olanzapine, quetiapine, or haloperidol) or valproic acid and its derivatives (as a nonantipsychotic

50 pine (relative risk=0.99, 95% CI=0.89-1.10), valproic acid and its derivatives (relative risk=0.91, 9

51 The use of valproic acid and its derivatives as alternative agents

52 l, olanzapine, quetiapine, and risperidone), valproic acid and its derivatives, or an antidepressant

53 peutic doses of the antiseizure medications, valproic acid and levetiracetam, did not improve behavio

54 Valproic acid and lithium are effective antibipolar drug

55 creases did not differ significantly between valproic acid and other medications.

56 For benzocaine, valproic acid and phenacetin several transformation prod

57 Valproic acid and related compounds warrant further inve

58 Both valproic acid and suberoylanilide hydroxamic acid inhibi

59 and S100A4 in R-cells were downregulated by valproic acid and suberoylanilide hydroxamic acid treatm

60 Exposure to valproic acid and suberoylanilide hydroxamic acid was as

61 r cells with histone deacetylase inhibitors, valproic acid and suberoylanilide hydroxamic acid, resto

62 The CEDIA kit for valproic acid and three substrates, a colorimetric (chlo

63 Furthermore, valproic acid and trichostatin A have remarkably similar

64 n with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat.

65 Mood stabilizers (e.g., valproic acid) and antipsychotic drugs (APDs) are common

66 rases (5-Azacytidine), histone deacetylases (valproic acid), and G9a histone dimethyltransferase.

67 neuropsychological effects of ethosuximide, valproic acid, and lamotrigine in children with newly di

68 TSA, valproic acid, and MS-275 repressed cytokine-induced MMP

69 lls cultured in the absence of CHIR99021 and valproic acid, and multilineage differentiation ability

70 ve molecules including estrone, lipoic acid, valproic acid, and probenecid.

71 The effectiveness of HDAC inhibitors, valproic acid, and suberoylanilide hydroxamic acid, in m

72 c (PK) monitoring of ketamine, propofol, and valproic acid, and their metabolites was achieved in mic

73 Valproic acid, another mood stabilizer, also increased t

74 orresponding PI values for phenobarbital and valproic acid are 1.37 and 5.18, respectively.

75 Lithium, carbamazepine and valproic acid are effective mood-stabilizing treatments

76 Disulfiram and valproic acid are known to inhibit ALDH5A1 and are safe

77 Lithium and valproic acid are mood-stabilizing agents that are often

78 Ethosuximide and valproic acid are more effective than lamotrigine in the

79 anticonvulsants, including carbamazepine and valproic acid, are effective antimanic drugs for treatin

80 dence, we calculate profiles for the neutral valproic acid as well as its water-soluble anionic conju

81 D) to study six environmental factors (lead, valproic acid, bisphenol A, ethanol, fluoxetine hydrochl

82 ortantly, the histone deacetylase inhibitor, valproic acid, blocked METH-induced decreased expression

83 hese B cell-intrinsic epigenetic mechanisms, valproic acid blunted class-switched and hypermutated T-

84 d and the commonly prescribed anticonvulsant valproic acid, both short-chain fatty acids (SCFAs), dra

85 as stable before addition of enfuvirtide and valproic acid, but declined thereafter.

86 Dictyostelium is sensitive to lithium and to valproic acid, but resistance to both is conferred by de

87 ropion, quetiapine, olanzapine, ziprasidone, valproic acid, carbamazepine, and citalopram were associ

88 t the anticonvulsant mood stabilizers (AMS), valproic acid, carbamazepine, and zonisamide, but not li

89 Valproic acid, chloral hydrate and newer-generation anti

90 e daily dose needed to maintain stable serum valproic acid concentration was 21% higher.

91 embryos, while non-teratogenic analogues of valproic acid do not inhibit histone deacetylase and do

92 mg/kg), phenobarbital (ED50 = 22 mg/kg), and valproic acid (ED50 = 133 mg/kg), which have PI values o

93 Furthermore, treatment with valproic acid enhanced posterior regeneration, leading t

94 In mice that received valproic acid (environmental cue), we demonstrated succe

95 nce efforts to mitigate prenatal exposure to valproic acid, especially for indications where the risk

96 This effect was disrupted in both valproic acid-exposed and Fmr1 knockout mice but intact

97 Despite its effects on the motor nuclei, valproic acid exposure did not alter the further develop

98 Valproic acid exposure induces the expression of the ste

99 Our findings suggest that valproic acid exposure may be associated with decreased

100 going 12 weeks of pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam).

101 a subset of patients from the Trial of Oral Valproic Acid for Retinitis Pigmentosa.

102 , combining three specific compounds, namely valproic acid, guanabenz, and a specific Caspase12 inhib

103 ned that the mood-stabilizing anticonvulsant valproic acid has a positive effect on both lipid compos

104 The action of valproic acid has been linked to both inositol depletion

105 ith the histone deacetylase (HDAC) inhibitor valproic acid, has previously demonstrated a promising a

106 Notably, valproic acid highly preserves the CD34 positivity after

107 r agonist ligand) obtained by conjugation to valproic acid (histone deacetylase inhibitor) via an est

108 Valproic acid, however, acts through a distinct pathway

109 short-chain fatty acids (sodium butyrate and valproic acid); hydroxamic acids (oxamflatin, Scriptaid,

110 re GR transcriptome and found that the KDACi valproic acid impairs the ability of agonist-bound GR to

111 istance protein (BCRP/ABCG2) upregulation by valproic acid in human brain endothelial cells via perox

112 reatment with paliperidone, lithium salt, or valproic acid in order to find similarities or differenc

113 fects and could also explain the efficacy of valproic acid in the treatment of bipolar disorder.

114 y distinct models of autism: mice exposed to valproic acid in utero and Fmr1 knockout mice.

115 or three AEDs (carbamazepine, phenytoin, and valproic acid), in the presence of serum, correlate well

116 Here, we show that valproic acid increases levels of exon 7-containing SMN

117 As the use of valproic acid increases, the number of both accidental a

118 histone deacetylase provides a mechanism for valproic acid-induced birth defects and could also expla

119 We find that valproic acid-induced expression of Galpha(i2) is inhibi

120 Valproic acid-induced gene expression has been attribute

121 Valproic acid-induced oxidative stress occurs in absence

122 Using K562 cells, we have studied valproic acid-induced transcription from the human Galph

123 es the survival rate of patients who develop valproic-acid-induced hepatotoxicity.

124 This is paralleled by more reports of valproic-acid-induced toxicity.

125 he use of carnitine as a treatment for acute valproic-acid-induced toxicity.

126 C) inhibitors, including sodium butyrate and valproic acid, induces 15-PGDH expression.

127 Static and kinetic properties of valproic acid interacting with fully hydrated dipalmitoy

128 ation of the class I-specific HDAC inhibitor valproic acid into bromodeoxyuridine (BrdU)-infused rats

129 Valproic acid is a safe and widely used neurologic agent

130 Valproic acid is a short branched fatty acid used as an

131 Interestingly, we show that valproic acid is a weak inhibitor of HDAC3 (IC(50) = 5.5

132 Valproic acid is a widely used anticonvulsant that has r

133 Valproic acid is frequently not recommended for patients

134 Valproic acid is widely used to treat epilepsy and bipol

135 A positive longevity effect was detected for valproic acid, isovaleric acid, and cyanocobalamin.

136 bstrates of the same enzymes (eg, tiagabine, valproic acid, lamotrigine, and topiramate).

137 present with coma, rising ammonia level, or valproic acid levels greater than 450 mg/l.

138 Valproic acid, like trichostatin A, also activates trans

139 ly pregnancy - thalidomide, misoprostol, and valproic acid; maternal rubella infection; and the organ

140 Use of valproic acid may be possible for some patients with hep

141 Valproic acid may increase SMN levels both by activating

142 At therapeutic levels, valproic acid mimics the histone deacetylase inhibitor t

143 cologically controlled and are aggravated by valproic acid monotherapy.

144 a cells were treated with cytokines and TSA, valproic acid, MS-275, or siRNA, and quantitative revers

145 that the gene expression-inducing effect of valproic acid occurs, in part, through the Sp family of

146 l, our results relate the changes induced by valproic acid on chromatin accessibility with the enhanc

147 s factor-alpha in the absence or presence of valproic acid or BAY11-7082 in vitro.

148 ad, exposing adult mice treated acutely with valproic acid or carrying a targeted deletion of the Nog

149 proach where class I HDAC inhibitors such as valproic acid or MS-275 (entinostat) appear to counterac

150 atment with a histone deacetylase inhibitor, valproic acid, or an acetyl donor, acetyl-carnitine (ALC

151 drome, is usually treated with ethosuximide, valproic acid, or lamotrigine.

152 ddition of the histone deacetylase inhibitor valproic acid partially reverses the reduced globin gene

153 ariants of the FXR gene, could contribute to valproic acid pharmacokinetic and toxicokinetic profile.

154 by providing a potential strategy to prevent valproic acid pharmacoresistance in epilepsy.

155 udy of patients of childbearing age who used valproic acid, pregnancy rates during valproic acid use

156 cause the total therapeutic concentration of valproic acid ranges from 275 to 700 mum in adults, thes

157 However, valproic acid remained the most effective second-line AS

158 s using the distance between the bilayer and valproic acid respective centers-of-mass along the bilay

159 Treatment with LiCl and valproic acid resulted in behavioural improvements and r

160 mparable to 2-keto-3-methyl-valeric acid and valproic acid, selective inhibitors for KGDH-mediated mt

161 Histone deacetylase inhibitors, including valproic acid, selectively induce cellular differentiati

162 Treatment with valproic acid showed steatosis induction in a lean backg

163 The Blimp-1 inhibitor valproic acid suppresses tumor growth in a B cell-depend

164 show that two small molecules, CHIR99021 and valproic acid, synergistically maintain self-renewal of

165 in nuclear extracts from cells treated with valproic acid than in control cells.

166 Attentional dysfunction was more common with valproic acid than with ethosuximide (in 49% of the chil

167 Among add-on regimens other than valproic acid, the combination of levetiracetam and lamo

168 euroactive carriers, namely, nicotinic acid, valproic acid, theophylline-7-acetic acid, and choline,

169 we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in

170 When cells were treated with valproic acid to induce neuronal differentiation, each o

171 lproex (DVX), which is chemically related to valproic acid, to enhance DA and ACh efflux in the HIP a

172 nable to use carnitine for documented severe valproic acid toxicity, particularly in cases where pati

173 e patients aged 12 to 44 years who initiated valproic acid treatment and had continuous insurance enr

174 The cohort included 165 772 valproic acid treatment episodes among 69 390 women (mea

175 Notably, valproic acid treatment increased pancreatic endoderm fo

176 Moreover, valproic acid treatment increases histone H4 acetylation

177 Resveratrol and valproic acid treatment of one of the CSC lines resulted

178 ALT changes in 564 individuals beginning valproic acid treatment were examined.

179 alanine aminotransferase (ALT) values during valproic acid treatment.

180 orrhagic shock/resuscitation was restored by valproic acid treatment.

181 entiate along the megakaryocyte lineage upon valproic acid treatment.

182 er RELA overexpression or NFKB/RELA inducer, valproic acid, treatment to result in reduced KIT expres

183 Assuming protonation of valproic acid upon association with--or insertion into--

184 ders accounted for the largest proportion of valproic acid use and had the highest pregnancy rates, w

185 7 to 2012 to examine the association between valproic acid use and melanoma risk.

186 tudies have explored the association between valproic acid use and melanoma risk.

187 o used valproic acid, pregnancy rates during valproic acid use did not decrease despite enhanced US F

188 Pregnancy incidence rates during valproic acid use remained unchanged, with a rate of 1.7

189 Teratogenic outcomes associated with valproic acid use represent a substantial concern for pe

190 and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute mye

191 recent report that short-term treatment with valproic acid (VA) might accelerate the decay of the lat

192 In pregnant women, delivery of valproic acid (VPA) (to control seizure activity or stab

193 the basis of in vitro synergistic effects of valproic acid (VPA) and all-trans retinoic acid with che

194 ound that both histone deacetylase inhibitor valproic acid (VPA) and DNA methylation inhibitor 5-azac

195 by the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and enhanced by the narrow-spectrum

196 Here, we tested 2 small molecules, valproic acid (VPA) and lithium (Li), to inhibit differe

197 induced by viral infection, is inhibited by valproic acid (VPA) and other histone deacetylase inhibi

198 tive to apoptosis induced by HDAC inhibitors valproic acid (VPA) and suberoylanilide hydroxamic acid

199 sensitive to histone deacetylase inhibitors valproic acid (VPA) and trichostatin A (TSA), recapitula

200 the histone deacetylase inhibitors (HDACis) valproic acid (VPA) and vorinostat.

201 stabilising drugs such as lithium (LiCl) and valproic acid (VPA) are the first line agents for treati

202 Lithium and valproic acid (VPA) are two primary drugs used to treat

203 (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect

204 Treatment with valproic acid (VPA) can induce oxidative stress, leading

205 proved histone deacetylase inhibitor (HDACi) valproic acid (VPA) corrects the folding and trafficking

206 air follicle-derived stem cells (HFSCs) with valproic acid (VPA) could enhance their survival and mig

207 n which we expose Xenopus laevis tadpoles to valproic acid (VPA) during a critical time point in brai

208 three etiologically distinct models-in utero valproic acid (VPA) exposure, CNTNAP2 knockout and FMR1

209 behavioral and cellular effects of prenatal valproic acid (VPA) exposure.

210 Valproic acid (VPA) has been widely used for decades to

211 Valproic acid (VPA) has been widely used in clinics for

212 Prenatal exposure to valproic acid (VPA) in humans has been associated with a

213 abine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia,

214 dministration of lithium chloride (LiCl) and valproic acid (VPA) in rats.

215 suggested that the nonlinear disposition of valproic acid (VPA) in the rat may be due to nonlinear d

216 nous rat model of ASD induced by exposure to valproic acid (VPA) in utero.

217 The mood-stabilizing agents lithium and valproic acid (VPA) increase DNA binding activity and tr

218 istone deacetylase (HDAC) inhibitors such as valproic acid (VPA) induce the expression of quiescent p

219 ly, combining NPI-0052 with either MS-275 or valproic acid (VPA) induced greater levels of cell death

220 demonstrated that exposure of these cells to valproic acid (VPA) induced mRNA, protein, and functiona

221 atment with the mood stabilizers lithium and valproic acid (VPA) induces synergistic neuroprotective

222 Here, we report that both lithium as well as valproic acid (VPA) inhibit beta-amyloid peptide (Abeta)

223 Recent evidence indicates that valproic acid (VPA) inhibits the immune response which f

224 Valproic acid (VPA) is a drug commonly used for epilepti

225 Valproic acid (VPA) is a proposed treatment for RP and o

226 The anticonvulsant valproic acid (VPA) is a well-known environmental risk f

227 Valproic acid (VPA) is a widely prescribed anticonvulsan

228 Valproic acid (VPA) is a widely used anticonvulsive agen

229 yzed, whether the HDAC class I/IIa inhibitor valproic acid (VPA) is able to attenuate atrial remodeli

230 Valproic acid (VPA) is among the most teratogenic of com

231 Valproic acid (VPA) is an anticonvulsant drug that is al

232 The histone deacetylase inhibitor valproic acid (VPA) is known for its anti-inflammatory a

233 In addition, two functional isomers of valproic acid (VPA) metabolites, 4-ene VPA and y-valprol

234 fects of the commonly used anti-seizure drug valproic acid (VPA) on chromatin accessibility were eluc

235 Dams received 350 mg/kg of valproic acid (VPA) on day 11.5 (the day of neural tube

236 hGaSC-gastruloids, we modeled the effects of valproic acid (VPA) on human gastrulation and uncovered

237 impact of the histone deacetylase inhibitor valproic acid (VPA) on Invs mutants.

238 s study, the effects of the antiseizure drug valproic acid (VPA) on the expression of genes that regu

239 We show here that the antiepileptic drug valproic acid (VPA) potently blocked seizure-induced neu

240 itions and psychiatric disorders affected by valproic acid (VPA) ranges from control of seizure and m

241 e demonstrate that the mood-stabilizing drug valproic acid (VPA) reduces sCD40L levels in plasma samp

242 ure to the highly teratogenic anticonvulsant valproic acid (VPA) significantly increases ASD prevalen

243 ing the histone deacetylase (HDAC) inhibitor valproic acid (VPA) to a histidine-tryptophan-ketoglutar

244 Delivery of valproic acid (VPA) to the human brain is relatively ine

245 emozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes i

246 Valproic acid (VPA) was found to enhance alpha7 integrin

247 Valproic acid (VPA) was the most effective HDACi, induci

248 ine and histone deacetylase (HDAC) inhibitor valproic acid (VPA) will reverse this increased risk.

249 ted that inhibiting class I HDACs, either by valproic acid (VPA), a class I specific HDAC inhibitor s

250 Our results show that valproic acid (VPA), a drug used to treat NR patients th

251 Here we report that valproic acid (VPA), a histone deacetylase inhibitor, en

252 associated with epigenetic changes and that valproic acid (VPA), a histone deacetylase inhibitor, ma

253 in Xenopus tadpoles after early exposure to valproic acid (VPA), a known teratogen associated with N

254 enous alpha-syn in neurons can be induced by valproic acid (VPA), a mood-stabilizer, anticonvulsant a

255 rons and assessed the cellular phenotypes of valproic acid (VPA), a teratogenic drug.

256 Valproic acid (VPA), a well-established therapy for seiz

257 Our laboratory has reported that valproic acid (VPA), an antiepileptic medication that ha

258 pilepsy and on colon/intestine inflammation, valproic acid (VPA), an effective antiepileptic drug in

259 In particular, valproic acid (VPA), an HDAC inhibitor, improves reprogr

260 Valproic acid (VPA), an histone deacetylase inhibitor, i

261 of the combination of 5-azacitidine (5-AZA), valproic acid (VPA), and ATRA in patients with acute mye

262 f the histone deacetylase inhibitor (HDACi), valproic acid (VPA), and epirubicin in solid tumor malig

263 lase (HDAC) inhibitors trichostatin A (TSA), valproic acid (VPA), and FK228 potentiated ATRA inductio

264 inhibitor of glucose uptake and glycolysis), valproic acid (VPA), and the ketogenic diet.

265 Valproic acid (VPA), another SCFA and an HDAC inhibitor,

266 We determined that valproic acid (VPA), currently undergoing a phase II tri

267 f CB CD34+ cells with the most active HDACI, valproic acid (VPA), following an initial 16-hour cytoki

268 Histone deacetylase inhibitors, such as valproic acid (VPA), have also been shown to have antian

269 ow that an inhibitor of histone deacetylase, valproic acid (VPA), induced neuronal differentiation of

270 phenotype of the liver of mice treated with valproic acid (VPA), or 2-propylpentanoic acid, a protot

271 e first 10 postnatal days, administration of valproic acid (VPA), the specific inhibitor for histone

272 porter, in this process and sensitization by valproic acid (VPA), which depletes glutathione and stim

273 Valproic acid (VPA), which, like NaB, belongs to the sho

274 well as the anticonvulsant mood-stabilizers, valproic acid (VPA), zonisamide, and carbamazepine, but

275 hree HDACis-CAY10603, vorinostat (SAHA), and valproic acid (VPA)-on human GBM cell lines (U87, MGG8)

276 morphology in animals prenatally exposed to valproic acid (VPA).

277 um butyrate (NaB), trichostatin A (TSA), and valproic acid (VPA).

278 nostat (suberoylanilide hydroxamic acid) and valproic acid (VPA).

279 chanism of action of a well-known teratogen, valproic acid (VPA).

280 hronic treatment with therapeutic dosages of valproic acid (VPA).

281 ancreatitis is due to the antiepileptic drug valproic acid (VPA).

282 atment with a histone deacetylase inhibitor, valproic acid (VPA).

283 ) is a chiral CNS-active amide derivative of valproic acid (VPA).

284 A combination of cytokines and valproic acid (VPA): (1) promoted the greatest degree of

285 creased by the histone deacetylase inhibitor valproic acid (VPA); however, UL138 inhibits the VPA-res

286 Therapeutic concentrations of valproic acid (VPA, 10-100 microM) inhibited both evoked

287 brain capillaries to the antiepileptic drug, valproic acid (VPA; 5 muM), significantly increased P-gl

288 (53% and 58%, respectively; odds ratio with valproic acid vs. ethosuximide, 1.26; 95% confidence int

289 2.66; 95% CI, 1.65 to 4.28; odds ratio with valproic acid vs. lamotrigine, 3.34; 95% CI, 2.06 to 5.4

290 OR, 0.59; 95% CI, 0.41-0.84), and the use of valproic acid was associated with increased odds of infe

291 sk of COVID-19 infection, whereas the use of valproic acid was associated with increased risk.

292 ALT elevations with valproic acid were significantly greater among patients

293 edom-from-failure rates for ethosuximide and valproic acid were similar (53% and 58%, respectively; o

294 psy using ASMs, especially carbamazepine and valproic acid, were at a higher risk for cardiac arrhyth

295 gs, mood stabilizers such as lithium ion and valproic acid, which are used to treat bipolar disorder,

296 partially restored by treating RS cells with valproic acid, which enhanced NKG2D-L surface expression

297 lico using transcriptomic changes induced by valproic-acid, which showed opposing effects in the two

298 The opposite applied to patients prescribed valproic acid, who had a higher risk of cardiovascular a

299 M30 in epilepsy toward health, most notably valproic acid, whose effect on M30 expression was replic

300 Combining valproic acid with imatinib showed significantly better